对研制的那格列奈片进行质量评价与研究。
To study and evaluate the quality of Nateglinide tablets the formulation is screened.
目的：建立那格列奈片的体外溶出度的测定方法。
OBJECTIVE To establish the dissolution method for nateglinide tablets.
最后，由于起效快，那格列奈造成低血糖风险相对较低。
Finally, owing to its rapid-action profile, nateglinide has a relatively low risk of causing hypoglycemia.
结论：方法简单、快速，可作为那格列奈的手性分离方法。
Conclusion: the proposed method is simple and can be used for the chiral separation of nateglinide.
结果表明：那格列奈具有B晶型、H晶型和S晶型三种结构。
The results indicate that nateglinide has three crystal forms, B-form, H-form and S-form.
摘要：目的评价那格列奈治疗2型糖尿病的有效性和安全性。
ABSTRACT: Objective To evaluate the efficacy and safety of nateglinide, a new antidiabetic agent, in the treatment of type 2 diabetes.
优选由那格列奈速释层与盐酸二甲双胍缓释层组成的双层片处方。
To optimize the formula of the double-layer tablet of nateglinide rapid-release layer and metformin hydrochloride sustained-release layer.
目的：探讨瑞格列奈治疗2型糖尿病患者的临床疗效以及使用安全性。
Objective: to study the nanotubes raigor column treatment of type 2 diabetic patients with clinical efficacy and safety of using.
那格列奈安全性、耐受性良好，极少发生低血糖，几乎不影响病人体重。
Nateglinide is safe and well tolerated with nearly no affects on the body weight of patients and rarely occurrence of hypoglycemia.
本文就格列奈类药物的药动学性质及与其他药物的药动学相互作用作一综述。
Pharmacokinetics of glinides and pharmacokinetic interactions with other drugs are reviewed in this paper.
前言： 目的：发现降糖药那格列奈另一种新的晶型结构，我们称之为S型。
Objective:A new crystal structure being assigued as S-form was found in nateglinide. The X-ray pattern and data were given and the melting point was determined.
与其他药物相比，格列美脲、格列吡嗪、格列本脲和瑞格列奈更容易导致低血糖。
Glimepiride, glipizide, glyburide and repaglinide lead to too-low blood sugar more often than other drugs do.
结论筛选的处方合理，制备工艺简单可行，制备的瑞格列奈片符合制剂质量要求。
Conclusion the reasonable formulation was obtained and preparation was simple, and the prepared tablets met the requirements.
结果：在所建立的最佳条件下，那格列奈对映体达到基线分离，分离度为1.68。
Result: Under the experiment conditions adopted, the baseline separation of nateglinide enantiomers was obtained, with the resolution 1.68.
目的：观察瑞格列奈、阿卡波糖联合治疗老年性2型糖尿病患者的临床疗效及安全性。
Objective: To observe the clinical efficacy and safety of combined treatment of repaglinide and acarbose in aged patients with diabetes type 2.
本发明涉及一种制备瑞格列奈中间体式(I)的方法，瑞格列奈为治疗糖尿病的药物。
The invention relates to a method for preparing a repaglinide intermediate in a formula (I), and repaglinide is a medicament for treating diabetes.
目的：观察瑞格列奈、阿卡波糖联合治疗老年性2型糖尿病患者的临床疗效及安全性。
Objective: To investigate the causes and clinical features of hypoglycemia in elderly patients with type 2 diabetes.
那格列奈是一种新型的非磺酰脲类促胰岛素分泌的降糖新药，其起效快且作用时间较短。
Nateglinide is a novel non-sulfonylurea antidiabetic agent by stimulating insulin secretion. Its action occurs rapidly and sustains shortly.
本文就早期相胰岛素分泌与糖尿病的关系、格列奈类药物的药理特性及临床应用等作一概述。
This article is to sum up the relationship between early phase of insulin secretion and diabetes mellitus, the pharmacological properties and clinical application of glinides.
用X射线衍射相分析法发现并确定降血糖新药那格列奈另一种新的晶型结构，我们称之为s型。
A new crystal structure of Nateglinide called s - out was found and determined by X - ray powder diffraction method. The pattern, data and the crystal size were given.
研制的那格列奈片质量可靠、工艺具有生产可行性，制订的质量标准可有效控制那格列奈片的质量。
The formulation and technics of Nateglinide tablets are feasible in practice and its quality criteria can effectively control.
考虑到其它试验中生活方式干预的强大效应，本研究的设计可能已经减少了那格列奈潜在利益的幅度。
Considering the powerful effects of lifestyle interventions in other trials, this design feature may have reduced the magnitude of the potential benefit from nateglinide.
结论化合物3,7,8,14有明显的降血糖活性，其中化合物3的降血糖活性与对照药那格列奈相当，值得进一步的研究。
Conclusion Compounds 3, 7, 8 and 14 showed good hypoglycemia activity. Compound 3 is worth further studying owing to its satisfactory activity.
结论化合物3,7,8,14有明显的降血糖活性，其中化合物3的降血糖活性与对照药那格列奈相当，值得进一步的研究。
Conclusion Compounds 3, 7, 8 and 14 showed good hypoglycemia activity. Compound 3 is worth further studying owing to its satisfactory activity.
应用推荐